Indraprastha Medical Corporation Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter
- September 16, 2026
- Posted by: Harsh Piplani
- Category: Results
Indraprastha Medical Corporation share price Rs 354.25 on 16 September 2026, down 0.08%. Q2 FY27 results date not confirmed. Q1 FY27 net profit Rs 56.00 crore. Q2 FY26 base a profit of Rs 49.00 crore.
Quick Answer
The Indraprastha Medical Corporation Q2 results date for FY27 is not confirmed, and Indraprastha Medical Corporation Ltd. had not filed a board meeting intimation with the NSE or BSE as of 16 September 2026. Indian listing rules require the September 2026 quarter results to be published within 45 days of the quarter end, an outer deadline of 14 November 2026. The quarter will be measured against a September 2025 base of Rs 381.00 crore in revenue and a profit of Rs 49.00 crore. This preview uses reported actuals only and carries no estimated revenue or profit figure for the coming quarter.
The Indraprastha Medical Corporation Q2 results FY27 announcement is the next scheduled earnings event for Indraprastha Medical Corporation Ltd., Indraprastha Medical Corporation operates a 718-bed tertiary care hospital in Delhi under a joint venture involving Apollo Hospitals and the Delhi government.. The stock traded at Rs 354.25 on the NSE on 16 September 2026, down 0.08% from the previous close of Rs 354.55, about 44.7% below its 52-week high of Rs 640.85 and 3.6% above its 52-week low of Rs 342.00.
What makes the Indraprastha Medical Corporation Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 381.00 crore of revenue and a profit of Rs 49.00 crore, while the most recent quarter on record, Q1 FY27, produced Rs 406.00 crore and a profit of Rs 56.00 crore. Everything below is built from those reported figures rather than from any forecast.
Click Here – Get Free Investment Predictions
When Is the Indraprastha Medical Corporation Q2 Results FY27 Date?
The Indraprastha Medical Corporation Q2 results date for FY27 is not confirmed. As of 16 September 2026, Indraprastha Medical Corporation Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.
What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Indraprastha Medical Corporation Q2 results date becomes public through that filing rather than through any advance announcement.
The Indraprastha Medical Corporation Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Indraprastha Medical Corporation.
Indraprastha Medical Corporation Q2 Results Expectations: What the Market Is Actually Tracking
No verified analyst estimate for the Indraprastha Medical Corporation Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Indraprastha Medical Corporation. The Indraprastha Medical Corporation Q2 results watchlist below is built from what the company has actually reported and disclosed.
Indraprastha Medical Corporation Q2 results are in focus as the Delhi hospital operator approaches the September 2026 quarter following a steady five-quarter run. Revenue moved from Rs 365 crore in the June 2025 quarter to Rs 381 crore in September 2025, eased slightly to Rs 372 crore in December 2025 and Rs 365 crore in March 2026, and then rose to Rs 406 crore in the June 2026 quarter. This gives Indraprastha Medical Corporation Q2 results a broadly stable revenue base with a modest dip in the middle quarters followed by a pickup, without any sharp swings or reported one-off items across this window for Indraprastha Medical Corporation Q2 results.
Operating margin for Indraprastha Medical Corporation eased from 20% in June 2025 to 19% in September 2025, then dipped further to 17% in both December 2025 and March 2026, before recovering to 20% in June 2026. Net profit followed a similar arc, moving from Rs 51 crore and Rs 49 crore in the first two quarters to Rs 41 crore in December 2025 and Rs 42 crore in March 2026, before climbing back to Rs 56 crore in June 2026, the highest of the five quarters. This is the core financial backdrop for Indraprastha Medical Corporation Q2 results heading into the next reporting period, showing a moderate mid-year margin compression that reversed, a detail relevant to Indraprastha Medical Corporation Q2 results overall.
On valuation, discussions of Indraprastha Medical Corporation Q2 results typically point to a trailing P/E of around 17.3x, a book value of Rs 80.8 per share, and a return on equity of 27.4% with return on capital employed at 35.8%, metrics that are comfortably strong for a hospital operator. The company also pays a dividend, with a yield of about 1.13%. Financial data used for Indraprastha Medical Corporation Q2 results is drawn from standalone results, since no separately reported consolidated financials were available for this entity, and the five quarters reviewed show no major anomalies or one-off items. Overall, the picture behind Indraprastha Medical Corporation Q2 results is one of consistency rather than volatility, though the data reflects results already reported rather than any forecast for the September 2026 quarter itself.
Check Indraprastha Medical Corporation Ltd. Live Fundamentals on the Univest Screener
Indraprastha Medical Corporation Q2 Results Preview: The Q1 FY27 Actuals It Builds On
Indraprastha Medical Corporation Ltd. reported revenue of Rs 406.00 crore in Q1 FY27, up 11.23% from Rs 365.00 crore in Q1 FY26, and a profit of Rs 56.00 crore at the net level, up 9.80% from Rs 51.00 crore in Q1 FY26. These are reported actuals, not estimates.
Sequentially, revenue was up 11.23% over the March 2026 quarter figure of Rs 365.00 crore, and net profit was up 33.33% from Rs 42.00 crore in Q4 FY26. Operating margin stood at 20.0% in Q1 FY27 against 19.0% in the September 2025 quarter, which is the comparison the Indraprastha Medical Corporation Q2 results print will be read against.
Q2 FY26 Base: The Comparison Indraprastha Medical Corporation Q2 Results FY27 Must Beat
Indraprastha Medical Corporation Ltd. reported revenue of Rs 381.00 crore and a profit of Rs 49.00 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Indraprastha Medical Corporation Q2 results preview.
Net profit in that base quarter was below the Rs 56.00 crore just reported for Q1 FY27, so the year-on-year comparison starts from a manageable level. Revenue of Rs 381.00 crore sits below the Rs 406.00 crore of the June 2026 quarter, which frames how much sequential movement the Indraprastha Medical Corporation Q2 results print needs to show growth.
Indraprastha Medical Corporation Quarterly Results Trend Over the Last Four Quarters
| Quarter | Revenue (Rs Cr) | Net Profit (Rs Cr) |
|---|---|---|
| Q2 FY26 (Sep 2025) | 381.00 | 49.00 |
| Q3 FY26 (Dec 2025) | 372.00 | 41.00 |
| Q4 FY26 (Mar 2026) | 365.00 | 42.00 |
| Q1 FY27 (Jun 2026) | 406.00 | 56.00 |
Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company’s exchange filings, and they are the only basis this Indraprastha Medical Corporation Q2 results preview uses.
Revenue across those four quarters ranged from Rs 365.00 crore to Rs 406.00 crore, and net profit from Rs 41.00 crore to Rs 56.00 crore. That spread is the honest context for the Indraprastha Medical Corporation Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.
Key Factors That Could Shape Indraprastha Medical Corporation Q2 Results FY27
The Indraprastha Medical Corporation Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Indraprastha Medical Corporation has already reported.
Valuation Snapshot
Indraprastha Medical Corporation trades at a trailing P/E of about 17.3x, supported by a book value of Rs 80.8 per share and a current price near Rs 354, which puts the price-to-book ratio at roughly 4.4x. Return on equity stands at a strong 27.4%, with return on capital employed even higher at 35.8%, reflecting healthy profitability for a hospital operator. The company pays a dividend yielding about 1.13%. These are relatively strong valuation and profitability metrics compared with many small and mid-cap peers, based on standalone financial data since consolidated figures are not separately available.
Technical and Price Context
Indraprastha Medical Corporation shares have ranged between Rs 342.00 and Rs 640.85 over the past 52 weeks, with the current price around Rs 354 sitting close to the lower end of that band. The stock trades below both its 50-day moving average of about Rs 368 and its 200-day moving average of about Rs 400, pointing to a soft recent trend relative to the longer-term average. The relative strength index is near 33, on the lower half of the 0 to 100 scale. This is a neutral technical snapshot rather than any buy or sell indication.
Balance Sheet and Payout
Indraprastha Medical Corporation carries a low debt-to-equity ratio of about 0.05, indicating the hospital operator funds its operations largely through equity rather than borrowed capital. The company pays a dividend with a yield of roughly 1.13%, consistent with steady, cash-generative operations. Balance sheet data is drawn from standalone financials, as no separate consolidated figures were available for this entity, and across the five quarters reviewed there are no major anomalies, write-offs, or one-off items affecting the payout or balance sheet picture.
Indraprastha Medical Corporation Q2 Results FY27: Share Price and Valuation Going Into the Print
Indraprastha Medical Corporation share price today is Rs 354.25 on the NSE, down Rs 0.30 or 0.08% from the previous close of Rs 354.55 on 16 September 2026, ahead of the Indraprastha Medical Corporation Q2 results announcement.
| Metric | Value (16 September 2026) |
|---|---|
| NSE Symbol | INDRAMEDCO |
| Current Market Price | Rs 354.25 |
| 52-Week High | Rs 640.85 |
| 52-Week Low | Rs 342.00 |
| Market Capitalisation | Rs 3243 crore |
| PE Ratio | 17.21 |
| PB Ratio | 4.38 |
| EPS (TTM) | Rs 20.58 |
| Book Value per Share | Rs 80.80 |
| Debt to Equity | 0.05 |
| Return on Equity | 27.4% |
| 50-Day Moving Average | Rs 368.18 |
| 200-Day Moving Average | Rs 399.55 |
| RSI (14) | 32.92 |
The stock trades below both its 50-day average of Rs 368.18 and its 200-day average of Rs 399.55, with a 14-day RSI of 32.92. None of this is a view on where the shares go once the Indraprastha Medical Corporation Q2 results are announced, and no price target is offered here.
Download the Univest iOS App or Univest Android App to track Indraprastha Medical Corporation Ltd. live price and quarterly earnings updates.
What Investors Should Watch When Indraprastha Medical Corporation Q2 Results Are Announced
Four lines carry most of the information in a company of this size, and reading them in order keeps the Indraprastha Medical Corporation Q2 results print in proportion.
- Revenue against the Rs 381.00 crore reported in the September 2025 base quarter
- Net profit against a profit of Rs 49.00 crore in that same quarter
- Operating margin against 20.0% in Q1 FY27
- Any exceptional item, provision or one-off gain disclosed alongside the numbers
A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Indraprastha Medical Corporation Q2 results announcement should be read together with the notes to the results rather than the headline alone.
Conclusion on Indraprastha Medical Corporation Q2 Results FY27
The Indraprastha Medical Corporation Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Indraprastha Medical Corporation Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.
On that basis the Indraprastha Medical Corporation Q2 results FY27 print faces a base of Rs 381.00 crore in revenue and a profit of Rs 49.00 crore, with the most recent quarter having delivered Rs 406.00 crore and a profit of Rs 56.00 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Indraprastha Medical Corporation, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Indraprastha Medical Corporation Q2 Results FY27
What is the Indraprastha Medical Corporation Q2 results date for FY27?
Ans. The Indraprastha Medical Corporation Q2 results date for FY27 is not confirmed. Indraprastha Medical Corporation Ltd. had not filed a board meeting intimation with the NSE or BSE as of 16 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.
What quarter do the Indraprastha Medical Corporation Q2 results 2026 cover?
Ans. The Indraprastha Medical Corporation Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Indraprastha Medical Corporation Ltd. reports revenue, operating profit and net profit for that period, and the Indraprastha Medical Corporation Q2 results filing also carries the notes to the accounts.
What were the Indraprastha Medical Corporation Q1 FY27 results?
Ans. Indraprastha Medical Corporation Ltd. reported revenue of Rs 406.00 crore in Q1 FY27 and a profit of Rs 56.00 crore at the net level. Revenue was up 11.23% versus Q1 FY26 and net profit was up 9.80% from Rs 51.00 crore in Q1 FY26.
What were Indraprastha Medical Corporation Q2 FY26 results in the September 2025 quarter?
Ans. Indraprastha Medical Corporation Ltd. reported revenue of Rs 381.00 crore and a profit of Rs 49.00 crore in Q2 FY26. Operating margin was 19.0%. Those figures form the base for the Indraprastha Medical Corporation Q2 results FY27 comparison.
What are the main Indraprastha Medical Corporation Q2 results expectations this quarter?
Ans. No verified analyst estimate is publicly available. The Indraprastha Medical Corporation Q2 results expectations centre on revenue against the Rs 381.00 crore base, net profit against a profit of Rs 49.00 crore, operating margin against 20.0% in Q1 FY27, and any exceptional item disclosed with the numbers.
What is Indraprastha Medical Corporation share price today ahead of the Q2 earnings?
Ans. Indraprastha Medical Corporation share price is Rs 354.25 on the NSE as of 16 September 2026, down 0.08% from Rs 354.55. The stock is about 44.7% below its 52-week high of Rs 640.85 and 3.6% above its 52-week low of Rs 342.00, at a market capitalisation of Rs 3243 crore.
Is Indraprastha Medical Corporation a good stock to buy before the Q2 results?
Ans. This article does not offer a buy, sell or hold recommendation on Indraprastha Medical Corporation Ltd. The stock trades at a price-to-book ratio of 4.38 with a return on equity of 27.4%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.
